A
Amir Attaran
Researcher at University of Ottawa
Publications - 118
Citations - 2469
Amir Attaran is an academic researcher from University of Ottawa. The author has contributed to research in topics: Public health & Essential medicines. The author has an hindex of 22, co-authored 118 publications receiving 2274 citations.
Papers
More filters
Journal ArticleDOI
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.
Edward J Mills,Jean B. Nachega,Jean B. Nachega,Iain Buchan,James Orbinski,Amir Attaran,Sonal Singh,Sonal Singh,Beth Rachlis,Ping Wu,Curtis Cooper,Lehana Thabane,Kumanan Wilson,Gordon H. Guyatt,David R. Bangsberg +14 more
TL;DR: The findings indicate that favorable levels of adherence, much of which was assessed via patient self-report, can be achieved in sub-Saharan African settings and that adherence remains a concern in North America.
Journal ArticleDOI
A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial.
Jon-David Schwalm,Tara McCready,Patricio Lopez-Jaramillo,Khalid Yusoff,Amir Attaran,Pablo Lamelas,Paul A. Camacho,Fadhlina Abd Majid,Shrikant I. Bangdiwala,Shrikant I. Bangdiwala,Lehana Thabane,Shofiqul Islam,Martin McKee,Salim Yusuf,Salim Yusuf +14 more
TL;DR: A comprehensive model of care led by NPHWs, involving primary care physicians and family that was informed by local context, substantially improved blood pressure control and cardiovascular disease risk is tested.
Journal ArticleDOI
Barriers to the effective treatment and prevention of malaria in Africa: A systematic review of qualitative studies
David M. Maslove,David M. Maslove,Anisa Mnyusiwalla,Anisa Mnyusiwalla,Edward J Mills,Edward J Mills,Jessie McGowan,Amir Attaran,Kumanan Wilson,Kumanan Wilson +9 more
TL;DR: Large-scale malaria prevention and treatment programs must account for the social and cultural contexts in which they are deployed, and barriers to malaria treatment and prevention are identified.
Posted Content
Combination Pharmacotherapy to Prevent Cardiovascular Disease: Present Status and Challenges
Salim Yusuf,Salim Yusuf,Salim Yusuf,Amir Attaran,Jackie Bosch,Jackie Bosch,Philip Joseph,Eva Lonn,Eva Lonn,Eva Lonn,Tara McCready,Andrew Mente,Robby Nieuwlaat,Prem Pais,Anthony Rodgers,J-D Schwalm,Richard Smith,Koon K. Teo,Denis Xavier +18 more
TL;DR: Acceptance of combination therapy in other settings suggests that with concerted efforts by academics, international health agencies, research funding bodies, governments, regulators, and pharmaceutical manufacturers, combination pills for prevention of CVD in those with disease or at high risk can be made available worldwide at affordable prices.
Journal ArticleDOI
Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.
Salim Yusuf,Amir Attaran,Jackie Bosch,Philip Joseph,Eva Lonn,Tara McCready,Andrew Mente,Robby Nieuwlaat,Prem Pais,Anthony Rodgers,J-D Schwalm,Richard Smith,Koon K. Teo,Denis Xavier +13 more
TL;DR: Combination pills containing aspirin, multiple blood pressure lowering drugs, and a statin have demonstrated safety, substantial risk factor reductions, and improved medication adherence in the prevention of cardiovascular disease (CVD) as discussed by the authors.